tetano
Editor, Senior Moderator
J Vis Exp. 2017 Dec 1;(130). doi: 10.3791/55833.
[h=1]An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers.[/h] Kaufmann L[SUP]1[/SUP], Syedbasha M[SUP]1[/SUP], Vogt D[SUP]1[/SUP], Hollenstein Y[SUP]1[/SUP], Hartmann J[SUP]1[/SUP], Linnik JE[SUP]2[/SUP], Egli A[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antibody titers are commonly used as surrogate markers for serological protection against influenza and other pathogens. Detailed knowledge of antibody production pre- and post-vaccination is required to understand vaccine-induced immunity. This article describes a reliable point-by-point protocol to determine influenza-specific antibody titers. The first protocol describes a method to specify the antigen amounts required for hemagglutination, which standardizes the concentrations for subsequent usage in the second protocol (hemagglutination assay, HA assay). The second protocol describes the quantification of influenza-specific antibody titers against different viral strains by using a serial dilution of human serum or cell culture supernatants (hemagglutination inhibition assay, HI assay). As an applied example, we show the antibody response of a healthy cohort, which received a trivalent inactivated influenza vaccine. Additionally, the cross-reactivity between the different influenza viruses is shown and methods to minimize cross-reactivity by using different types of animal red blood cells (RBCs) are explained. The discussion highlights advantages and disadvantages of the presented assays and how the determination of influenza-specific antibody titers can improve the understanding of vaccine-related immunity.
PMID: 29286466 DOI: 10.3791/55833
[h=1]An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers.[/h] Kaufmann L[SUP]1[/SUP], Syedbasha M[SUP]1[/SUP], Vogt D[SUP]1[/SUP], Hollenstein Y[SUP]1[/SUP], Hartmann J[SUP]1[/SUP], Linnik JE[SUP]2[/SUP], Egli A[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Antibody titers are commonly used as surrogate markers for serological protection against influenza and other pathogens. Detailed knowledge of antibody production pre- and post-vaccination is required to understand vaccine-induced immunity. This article describes a reliable point-by-point protocol to determine influenza-specific antibody titers. The first protocol describes a method to specify the antigen amounts required for hemagglutination, which standardizes the concentrations for subsequent usage in the second protocol (hemagglutination assay, HA assay). The second protocol describes the quantification of influenza-specific antibody titers against different viral strains by using a serial dilution of human serum or cell culture supernatants (hemagglutination inhibition assay, HI assay). As an applied example, we show the antibody response of a healthy cohort, which received a trivalent inactivated influenza vaccine. Additionally, the cross-reactivity between the different influenza viruses is shown and methods to minimize cross-reactivity by using different types of animal red blood cells (RBCs) are explained. The discussion highlights advantages and disadvantages of the presented assays and how the determination of influenza-specific antibody titers can improve the understanding of vaccine-related immunity.
PMID: 29286466 DOI: 10.3791/55833